Integrated Assessment of Immune-Inflammatory and Metabolic Biomarkers for Prediction of Coronary No-Reflow Following Primary PCI in STEMI Patients

Condition(s) studied

Investigational drug(s) / intervention(s)

Assessment of immune-inflammatory and metabolic biomarkers: Venous blood samples will be collected on admission before primary percutaneous coronary intervention for complete blood count and biochemical analysis. Laboratory results will be used to calculate the Systemic Immune-Inflammation Index (SII), neutrophil-to-lymphocyte ratio (NLR), Systemic Inflammatory Response Index (SIRI), Triglyceride-Glucose (TyG) index, and uric acid-to-HDL cholesterol ratio (UHR).

Study summary

This study aims to evaluate the combined predictive value of immune-inflammatory and metabolic biomarkers for coronary no-reflow following primary percutaneous coronary intervention (PCI) in patients with ST-segment elevation myocardial infarction (STEMI), with the goal of improving early risk stratification and clinical decision-making.

Eligibility

Primary outcome measure(s)

• Predictive performance of the Systemic Immune-Inflammation Index (SII) for coronary no-reflow — During the primary percutaneous coronary intervention (Day 1).
  Predictive performance of admission Systemic Immune-Inflammation Index (SII), calculated as platelet count × neutrophil count / lymphocyte count, for coronary no-reflow following primary percutaneous coronary intervention (PCI), assessed using the area under the receiver operating characteristic (ROC) curve.

Trial sites (1)

More Sohag University trials in Egypt

Other trials for the same condition